Related Experiment Videos
How does fingolimod (gilenya(®)) fit in the treatment algorithm for highly active relapsing-remitting multiple
Franz Fazekas1, Ovidiu Bajenaru, Thomas Berger
1Department of Neurology, Medical University of Graz Graz, Austria.
Frontiers in Neurology
|May 4, 2013
Summary
Fingolimod is the first oral medication for multiple sclerosis (MS), offering a new treatment option for highly active relapsing-remitting MS (RRMS). Experts discussed its benefits and risks for patient management.
Area of Science:
- Neurology
- Immunology
Background:
- Multiple sclerosis (MS) is a central nervous system disorder involving inflammation and neurodegeneration.
- Current MS treatments often require injections and have moderate efficacy or severe side effects.
- Fingolimod represents a significant advancement as the first oral disease-modifying therapy for MS.
Purpose of the Study:
- To discuss the clinical benefits and risks of fingolimod in managing multiple sclerosis (MS).
- To integrate fingolimod into the existing treatment algorithm for MS.
- To provide expert guidance on patient selection and management for fingolimod therapy.
Main Methods:
- Expert meeting discussion on fingolimod's role in MS treatment.
- Review of clinical data on efficacy and safety.
- Development of treatment recommendations for highly active relapsing-remitting MS (RRMS).
Main Results:
- Fingolimod is approved for highly active RRMS in adult patients.
- It is suitable for patients with high disease activity despite basic treatment or rapidly evolving severe RRMS.
- Experts provided consensus on fingolimod's place in MS therapy.
Conclusions:
- Fingolimod offers a new oral treatment option for specific MS patient populations.
- Careful patient selection and management are crucial for optimizing fingolimod therapy.
- The expert discussion aimed to guide the use of this novel MS treatment.
Related Concept Videos
01:20Myasthenia Gravis: Overview and Treatment
Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
01:19Multiple Sclerosis l: Introduction
Multiple sclerosis is a chronic autoimmune disease of the central nervous system (CNS) that affects the brain, spinal cord, and optic nerves. It is an inflammatory demyelinating disorder and a leading cause of neurological disability in young adults.EpidemiologyMS commonly begins between 20 and 40 years of age and is twice as common in women. Its exact cause remains unclear, but genetic susceptibility contributes, with higher risk in first-degree relatives and identical twins. A greater...
01:20Antiepileptic Drugs: Potassium Channel Activators
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
01:22Alzheimer's Disease: Treatment
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
01:24Parkinson's Disease: Treatment
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of its...
01:24Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...